首页 > 最新文献

Revista Portuguesa de Cardiologia (English Edition)最新文献

英文 中文
Medication adherence to direct anticoagulants in patients with non-valvular atrial fibrillation – A real world analysis 非瓣膜性心房颤动患者对直接抗凝药物的依从性——一项真实世界的分析
Pub Date : 2021-09-01 DOI: 10.1016/j.repce.2021.07.002
Catarina Brízido, António Miguel Ferreira, Pedro Lopes, Christopher Strong, Gustavo Sá Mendes, Francisco Fernandes Gama, Anaí Durazzo, Gustavo Rocha Rodrigues, Daniel Matos, Sara Guerreiro, Sérgio Madeira, Jorge Ferreira, Pedro Adragão, Miguel Mendes

Introduction

Direct oral anticoagulants (DOACs) changed the landscape of atrial fibrillation (AF) treatment, but also brought with them new challenges in terms of accessibility and compliance. The purpose of this study was to assess adherence to DOACs, and its determinants in a population of AF patients.

Methods

Single-center retrospective study including all patients with non-valvular AF treated with a DOAC from the outpatient general cardiology list at a tertiary center, whose first DOAC prescription was between 1 April 2016 and August 2018. The number of pharmacy refills from the day of first prescription to 31 August 2018 was counted (by means of an electronic prescription platform). Medication refill adherence (MRA) was calculated by dividing the total days' supply by the number of days under therapy. Non-compliance was defined as MRA <90%.

Results

A total of 264 patients (120 men, mean age 74 ± 12 years) met the inclusion criteria. The median CHA2DS2VASC score was 3 (interquartile range (IQR) 2-5) and the median HAS-BLED was 1 (IQR 1-2). Rivaroxaban, apixaban, dabigatran and edoxaban were prescribed in 45%, 41%, 24% and 13% of patients, respectively. During the study 51 patients (19%) used at least two DOACs .Patients took DOACs for a median period of 439 days (IQR 269-638), during which the included population adhered to therapy 90% of the time (IQR 75-100%). Half of the patients (51%) were classified as non-compliant; therapy duration (adjusted odds ratio 1.06 per month, 95% confidence interval (CI) 1.03-1.08, p<0.001), DOACs twice daily (adjusted OR 1.73, 95%CI 1.08-2.75, p=0.022), and higher out-of-pocket costs (adjusted OR 2.13, 95%CI 1.28-3.45, p=0.003) were independent predictors of non-compliance.

Conclusion

Half of the patients (51%) were classified as non-compliant (medication refill adherence <90%). Therapy duration, DOACs twice daily and higher out out-of-pocket costs were independent predictors of non-compliance, which could be targets to improve patient adherence.

直接口服抗凝剂(DOACs)改变了心房颤动(AF)治疗的格局,但也带来了可及性和依从性方面的新挑战。本研究的目的是评估房颤患者对DOACs的依从性及其决定因素。方法采用单中心回顾性研究,纳入2016年4月1日至2018年8月期间在某三级中心门诊普通心脏病学名单中首次使用DOAC治疗的所有非瓣膜性房颤患者。统计自首次开处方之日起至2018年8月31日止药房补药次数(通过电子处方平台)。药物补充依从性(MRA)通过总供应天数除以治疗天数来计算。不符合定义为MRA <90%。结果264例患者(男性120例,平均年龄74 ± 12岁)符合纳入标准。CHA2DS2VASC评分中位数为3(四分位范围(IQR) 2-5), ha - bled评分中位数为1 (IQR 1-2)。利伐沙班、阿哌沙班、达比加群和依多沙班分别占45%、41%、24%和13%。在研究期间,51名患者(19%)至少使用了两种DOACs。患者服用DOACs的中位时间为439天(IQR 269-638),在此期间,纳入的人群有90%的时间(IQR 75-100%)坚持治疗。一半的患者(51%)被归类为不依从性;治疗持续时间(调整后的优势比为1.06 /月,95%可信区间(CI) 1.03-1.08, p<0.001)、每日两次DOACs(调整后的OR为1.73,95%CI为1.08-2.75,p=0.022)和较高的自费费用(调整后的OR为2.13,95%CI为1.28-3.45,p=0.003)是不依从性的独立预测因素。结论半数(51%)患者属于不依从性(药物补充依从性占90%)。治疗持续时间、每日两次doac和较高的自付费用是不依从性的独立预测因素,这可能是提高患者依从性的目标。
{"title":"Medication adherence to direct anticoagulants in patients with non-valvular atrial fibrillation – A real world analysis","authors":"Catarina Brízido,&nbsp;António Miguel Ferreira,&nbsp;Pedro Lopes,&nbsp;Christopher Strong,&nbsp;Gustavo Sá Mendes,&nbsp;Francisco Fernandes Gama,&nbsp;Anaí Durazzo,&nbsp;Gustavo Rocha Rodrigues,&nbsp;Daniel Matos,&nbsp;Sara Guerreiro,&nbsp;Sérgio Madeira,&nbsp;Jorge Ferreira,&nbsp;Pedro Adragão,&nbsp;Miguel Mendes","doi":"10.1016/j.repce.2021.07.002","DOIUrl":"10.1016/j.repce.2021.07.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Direct oral anticoagulants (DOACs) changed the landscape of atrial fibrillation (AF) treatment, but also brought with them new challenges in terms of accessibility and compliance. The purpose of this study was to assess adherence to DOACs, and its determinants in a population of AF patients.</p></div><div><h3>Methods</h3><p>Single-center retrospective study including all patients with non-valvular AF treated with a DOAC from the outpatient general cardiology list at a tertiary center, whose first DOAC prescription was between 1 April 2016 and August 2018. The number of pharmacy refills from the day of first prescription to 31 August 2018 was counted (by means of an electronic prescription platform). Medication refill adherence (MRA) was calculated by dividing the total days' supply by the number of days under therapy. Non-compliance was defined as MRA &lt;90%.</p></div><div><h3>Results</h3><p>A total of 264 patients (120 men, mean age 74 ± 12 years) met the inclusion criteria. The median CHA<sub>2</sub>DS<sub>2</sub>VAS<sub>C</sub> score was 3 (interquartile range (IQR) 2-5) and the median HAS-BLED was 1 (IQR 1-2). Rivaroxaban, apixaban, dabigatran and edoxaban were prescribed in 45%, 41%, 24% and 13% of patients, respectively. During the study 51 patients (19%) used at least two DOACs .Patients took DOACs for a median period of 439 days (IQR 269-638), during which the included population adhered to therapy 90% of the time (IQR 75-100%). Half of the patients (51%) were classified as non-compliant; therapy duration (adjusted odds ratio 1.06 per month, 95% confidence interval (CI) 1.03-1.08, p&lt;0.001), DOACs twice daily (adjusted OR 1.73, 95%CI 1.08-2.75, p=0.022), and higher out-of-pocket costs (adjusted OR 2.13, 95%CI 1.28-3.45, p=0.003) were independent predictors of non-compliance.</p></div><div><h3>Conclusion</h3><p>Half of the patients (51%) were classified as non-compliant (medication refill adherence &lt;90%). Therapy duration, DOACs twice daily and higher out out-of-pocket costs were independent predictors of non-compliance, which could be targets to improve patient adherence.</p></div>","PeriodicalId":101121,"journal":{"name":"Revista Portuguesa de Cardiologia (English Edition)","volume":"40 9","pages":"Pages 669-675"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.repce.2021.07.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39402076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Reply to “Basal takotsubo syndrome: a multifaceted entity with potential implications” and an update assessing myocardial work 回复“基底takotsubo综合征:具有潜在影响的多方面实体”和评估心肌工作的最新进展
Pub Date : 2021-08-01 DOI: 10.1016/j.repce.2021.08.001
Nikolaos Miaris, Nearchos Kasinos, Maria Karakosta, Sarantos Linardakis, Dimitra Maritsa, Nikolaos Patsourakos, Evangelos Pisimisis
{"title":"Reply to “Basal takotsubo syndrome: a multifaceted entity with potential implications” and an update assessing myocardial work","authors":"Nikolaos Miaris,&nbsp;Nearchos Kasinos,&nbsp;Maria Karakosta,&nbsp;Sarantos Linardakis,&nbsp;Dimitra Maritsa,&nbsp;Nikolaos Patsourakos,&nbsp;Evangelos Pisimisis","doi":"10.1016/j.repce.2021.08.001","DOIUrl":"10.1016/j.repce.2021.08.001","url":null,"abstract":"","PeriodicalId":101121,"journal":{"name":"Revista Portuguesa de Cardiologia (English Edition)","volume":"40 8","pages":"Pages 627-630"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.repce.2021.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39311163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac arrhythmias in patients presenting with COVID-19 treated in Portuguese hospitals: A national registry from the Portuguese Association of Arrhythmology, Pacing and Electrophysiology 在葡萄牙医院接受治疗的COVID-19患者的心律失常:葡萄牙心律失常、起搏和电生理学协会的国家登记处
Pub Date : 2021-08-01 DOI: 10.1016/j.repce.2020.11.025
Dinis Mesquita , Pedro Carmo , Nuno Cabanelas , Nuno Santos , Vítor Martins , Victor Sanfins , Helena Cristina Costa , José Paulo Fontes , Paulo Fonseca , Leonor Parreira , on behalf of the Portuguese Association of Arrhythmology, Pacing and Electrophysiology (APAPE)

Introduction and objectives

In December 2019, SARS-CoV-2, was discovered as the agent of COVID-19 disease. Cardiac arrhythmias have been reported as frequent but their incidence is unknown. The aim of this research was to assess the real incidence of cardiac arrhythmias among COVID-19 patients admitted to Portuguese hospitals and to understand the underlying prognostic implications.

Methods

The Portuguese Association of Arrhythmology, Pacing and Electrophysiology (APAPE) conducted a survey in Portuguese hospitals to assess the occurrence of arrhythmias in COVID-19 patients, their clinical characteristics, the use of experimental therapies and the impact on QT interval.

Results

Twenty hospitals participated, reporting 692 hospitalized patients. An arrhythmic episode occurred in 81 (11.7%) and 64 (79%) had detailed information on these episodes. New onset arrhythmias occurred in 41 (64%) patients, 45 (70.3%) male, median age 73.5 (61-80.3) years. There were 51 (79.7%) with associated comorbidities, mainly arterial hypertension (41, 64.1%). Of 53 patients (82.3%) on experimental therapy, 7 (10.9%) had an increased QTc interval. Regarding arrhythmias, two patients (3.1%) had ventricular tachycardia, 5 (7.8%) sinus bradycardia, 17 (26.6%) paroxysmal supraventricular tachycardia and 40 (62.5%) atrial fibrillation or flutter. At the time of reporting, there had been no deaths due to arrhythmic syndrome or related complications.

Conclusions

In a population of COVID-19 patients. The incidence of cardiac arrhythmias is high but not associated with increased cardiac mortality although it does though occur frequently in extremely ill patients and with multiple organ failure. Regardless of the use of experimental drugs, the incidence of ventricular arrhythmias is low and atrial fibrillation and other supraventricular arrhythmias are the most prevalent arrythmias.

2019年12月,SARS-CoV-2被发现是COVID-19疾病的病原体。心律失常已被报道为频繁,但其发病率尚不清楚。本研究的目的是评估葡萄牙医院收治的COVID-19患者心律失常的真实发生率,并了解潜在的预后影响。方法葡萄牙心律失常、起搏与电生理协会(APAPE)对葡萄牙医院进行调查,评估COVID-19患者心律失常的发生情况、临床特点、实验疗法的使用情况及对QT间期的影响。结果20家医院参与调查,报告住院患者692例。81例(11.7%)发生心律失常,64例(79%)有这些发作的详细信息。新发心律失常41例(64%),男性45例(70.3%),中位年龄73.5(61 ~ 80.3)岁。51例(79.7%)伴有相关合并症,以动脉高血压为主(41例,64.1%)。53例(82.3%)接受实验性治疗的患者中,7例(10.9%)QTc间期增加。在心律失常方面,2例(3.1%)为室性心动过速,5例(7.8%)为窦性心动过速,17例(26.6%)为阵发性室上性心动过速,40例(62.5%)为心房颤动或扑动。在提交报告时,没有因心律失常综合征或相关并发症而死亡的病例。结论在新冠肺炎患者人群中。心律失常的发生率很高,但与心脏死亡率的增加无关,尽管它经常发生在重病患者和多器官衰竭患者中。无论使用何种实验性药物,室性心律失常的发生率都很低,房颤和其他室上性心律失常是最常见的心律失常。
{"title":"Cardiac arrhythmias in patients presenting with COVID-19 treated in Portuguese hospitals: A national registry from the Portuguese Association of Arrhythmology, Pacing and Electrophysiology","authors":"Dinis Mesquita ,&nbsp;Pedro Carmo ,&nbsp;Nuno Cabanelas ,&nbsp;Nuno Santos ,&nbsp;Vítor Martins ,&nbsp;Victor Sanfins ,&nbsp;Helena Cristina Costa ,&nbsp;José Paulo Fontes ,&nbsp;Paulo Fonseca ,&nbsp;Leonor Parreira ,&nbsp;on behalf of the Portuguese Association of Arrhythmology, Pacing and Electrophysiology (APAPE)","doi":"10.1016/j.repce.2020.11.025","DOIUrl":"10.1016/j.repce.2020.11.025","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>In December 2019, SARS-CoV-2, was discovered as the agent of COVID-19 disease. Cardiac arrhythmias have been reported as frequent but their incidence is unknown. The aim of this research was to assess the real incidence of cardiac arrhythmias among COVID-19 patients admitted to Portuguese hospitals and to understand the underlying prognostic implications.</p></div><div><h3>Methods</h3><p>The Portuguese Association of Arrhythmology, Pacing and Electrophysiology (APAPE) conducted a survey in Portuguese hospitals to assess the occurrence of arrhythmias in COVID-19 patients, their clinical characteristics, the use of experimental therapies and the impact on QT interval.</p></div><div><h3>Results</h3><p>Twenty hospitals participated, reporting 692 hospitalized patients. An arrhythmic episode occurred in 81 (11.7%) and 64 (79%) had detailed information on these episodes. New onset arrhythmias occurred in 41 (64%) patients, 45 (70.3%) male, median age 73.5 (61-80.3) years. There were 51 (79.7%) with associated comorbidities, mainly arterial hypertension (41, 64.1%). Of 53 patients (82.3%) on experimental therapy, 7 (10.9%) had an increased QTc interval. Regarding arrhythmias, two patients (3.1%) had ventricular tachycardia, 5 (7.8%) sinus bradycardia, 17 (26.6%) paroxysmal supraventricular tachycardia and 40 (62.5%) atrial fibrillation or flutter. At the time of reporting, there had been no deaths due to arrhythmic syndrome or related complications.</p></div><div><h3>Conclusions</h3><p>In a population of COVID-19 patients. The incidence of cardiac arrhythmias is high but not associated with increased cardiac mortality although it does though occur frequently in extremely ill patients and with multiple organ failure. Regardless of the use of experimental drugs, the incidence of ventricular arrhythmias is low and atrial fibrillation and other supraventricular arrhythmias are the most prevalent arrythmias.</p></div>","PeriodicalId":101121,"journal":{"name":"Revista Portuguesa de Cardiologia (English Edition)","volume":"40 8","pages":"Pages 573-580"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.repce.2020.11.025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39311723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Is lipid accumulation product a better cardiovascular risk predictor in elderly individuals than anthropometric measures? 脂质积累产物比人体测量指标更能预测老年人心血管风险吗?
Pub Date : 2021-08-01 DOI: 10.1016/j.repce.2020.09.007
Samon Henrique Nunes , Maria Auxiliadora Nogueira Saad , Rubens Antunes da Cruz Filho , Antonio José Lagoeiro Jorge , Márcia Maria Sales dos Santos , Wolney de Andrade Martins , Thais Landi de Campos , Maria Luiza Garcia Rosa

Introduction

Population aging is associated with increased prevalence of cardiovascular diseases that have a significant impact on overall morbidity and mortality. Insulin resistance (IR) and visceral obesity are risk factors for vascular damage and cardiometabolic diseases.

Aims

Estimating the correlation between lipid accumulation product (LAP) and IR in elderly individuals and comparing them to traditional anthropometric indices.

Methods

Cross-sectional study comprising 411 individuals >60 years, who were treated in a primary care service. Body mass index (BMI), neck circumference (NC), waist circumference (WC), hip circumference (HC), arm circumference (AC), sagittal abdominal diameter (SAD) and waist-hip ratio (WHR) were recorded. IR was estimated based on HOMA-IR (homeostasis model assessment IR index). LAPa index was calculated as [WC-65]×[triglyceride (TG)] in men, and as [WC-58]×[TG] in women, whereas LAPb was calculated by using the minimum WC values recorded for the current sample, i.e., 61.5 cm for women and 71.5 cm for men.

Results

There was correlation among LAPa (0.506), LAPb (0.515) and HOMA-IR. LAP was better correlated to HOMA-IR and showed higher area under the curve than BMI, NC, WHR and SAD. Based on the receiver operating characteristic curve analysis, LAPb≥47.40 and LAPa≥52.5 were the best cut-off values used to identify individuals with IR presenting 68.8% and 68.2% sensitivity, and 68.6% and 68.6% specificity, respectively.

Conclusion

LAP may be a useful and simple clinical marker to assess cardiometabolic risk factors in the elderly population treated at a primary care service.

人口老龄化与心血管疾病患病率增加有关,心血管疾病对总体发病率和死亡率有重大影响。胰岛素抵抗(IR)和内脏性肥胖是血管损伤和心脏代谢疾病的危险因素。目的评估老年人脂质积累产物(LAP)与IR之间的相关性,并将其与传统的人体测量指标进行比较。方法横断面研究包括411名60岁的在初级保健服务机构接受治疗的个体。记录体重指数(BMI)、颈围(NC)、腰围(WC)、臀围(HC)、臂围(AC)、矢状腹径(SAD)、腰臀比(WHR)。IR是根据HOMA-IR(稳态模型评估IR指数)来估计的。LAPa指数在男性中计算为[WC-65]×[甘油三酯(TG)],在女性中计算为[WC-58]×[TG],而LAPb是通过使用当前样本记录的最小WC值来计算的,即女性为61.5 cm,男性为71.5 cm。结果LAPa(0.506)、LAPb(0.515)与HOMA-IR相关。LAP与HOMA-IR相关性较好,曲线下面积高于BMI、NC、WHR和SAD。根据受试者工作特征曲线分析,LAPb≥47.40和LAPa≥52.5是识别IR个体的最佳临界值,敏感性分别为68.8%和68.2%,特异性分别为68.6%和68.6%。结论lap可作为一种简便、有效的临床指标,用于评价接受初级保健服务的老年人群的心脏代谢危险因素。
{"title":"Is lipid accumulation product a better cardiovascular risk predictor in elderly individuals than anthropometric measures?","authors":"Samon Henrique Nunes ,&nbsp;Maria Auxiliadora Nogueira Saad ,&nbsp;Rubens Antunes da Cruz Filho ,&nbsp;Antonio José Lagoeiro Jorge ,&nbsp;Márcia Maria Sales dos Santos ,&nbsp;Wolney de Andrade Martins ,&nbsp;Thais Landi de Campos ,&nbsp;Maria Luiza Garcia Rosa","doi":"10.1016/j.repce.2020.09.007","DOIUrl":"10.1016/j.repce.2020.09.007","url":null,"abstract":"<div><h3>Introduction</h3><p>Population aging is associated with increased prevalence of cardiovascular diseases that have a significant impact on overall morbidity and mortality. Insulin resistance (IR) and visceral obesity are risk factors for vascular damage and cardiometabolic diseases.</p></div><div><h3>Aims</h3><p>Estimating the correlation between lipid accumulation product (LAP) and IR in elderly individuals and comparing them to traditional anthropometric indices.</p></div><div><h3>Methods</h3><p>Cross-sectional study comprising 411 individuals &gt;60 years, who were treated in a primary care service. Body mass index (BMI), neck circumference (NC), waist circumference (WC), hip circumference (HC), arm circumference (AC), sagittal abdominal diameter (SAD) and waist-hip ratio (WHR) were recorded. IR was estimated based on HOMA-IR (homeostasis model assessment IR index). LAP<sup>a</sup> index was calculated as [WC-65]×[triglyceride (TG)] in men, and as [WC-58]×[TG] in women, whereas LAP<sup>b</sup> was calculated by using the minimum WC values recorded for the current sample, i.e., 61.5 cm for women and 71.5 cm for men.</p></div><div><h3>Results</h3><p>There was correlation among LAP<sup>a</sup> (0.506), LAP<sup>b</sup> (0.515) and HOMA-IR. LAP was better correlated to HOMA-IR and showed higher area under the curve than BMI, NC, WHR and SAD. Based on the receiver operating characteristic curve analysis, LAP<sup>b</sup>≥47.40 and LAP<sup>a</sup>≥52.5 were the best cut-off values used to identify individuals with IR presenting 68.8% and 68.2% sensitivity, and 68.6% and 68.6% specificity, respectively.</p></div><div><h3>Conclusion</h3><p>LAP may be a useful and simple clinical marker to assess cardiometabolic risk factors in the elderly population treated at a primary care service.</p></div>","PeriodicalId":101121,"journal":{"name":"Revista Portuguesa de Cardiologia (English Edition)","volume":"40 8","pages":"Pages 539-544"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.repce.2020.09.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39311720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Heart and brain interactions in heart failure: Cognition, depression, anxiety, and related outcomes 心力衰竭中的心脏和大脑相互作用:认知、抑郁、焦虑和相关结果
Pub Date : 2021-08-01 DOI: 10.1016/j.repce.2020.09.008
Joana Rigueira , João R. Agostinho , Inês Aguiar-Ricardo , Inês Gonçalves , Rafael Santos , Afonso Nunes-Ferreira , Tiago Rodrigues , Nelson Cunha , N’Zinga André , Raquel Pires , Fátima Veiga , Mónica Mendes Pedro , Fausto J. Pinto , Dulce Brito

Background

Cognitive impairment, anxiety and depression are common in heart failure (HF) patients and its evolution is not fully understood.

Objectives

To assess the cognitive status of HF patients over time, its relation to anxiety and depression, and its prognostic impact.

Methods

Prospective, longitudinal, single center study including patients enrolled in a structured program for follow-up after hospital admission for HF decompensation. Cognitive function, anxiety/depression state, HF-related quality of life (QoL) were assessed before discharge and during follow-up (between 6th and 12th month) using Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS) and Kansas City Cardiomyopathy Questionnaire, respectively. HF related outcomes were all cause readmissions, HF readmissions and the composite endpoint of all-cause readmissions or death.

Results

43 patients included (67±11.3 years, 69% male); followed-up for 8.2±2.1 months. 25.6% had an abnormal MoCA score that remained stable during follow-up (22.6±4.2 vs. 22.2±5.5; p=NS). MoCA score <22 at discharge conferred a sixfold greater risk of HF readmission [HR=6.42 (1.26-32.61); p=0.025], also predicting all-cause readmissions [HR=4.00 (1.15-13.95); p=0.03] and death or all-cause readmissions [HR=4.63 (1.37-15.67); p=0.014]. Patients with higher MoCA score showed a greater ability to deal with their disease (p=0.038). At discharge, 14% and 18.6% had an abnormal HADS score for depression and anxiety, respectively, which remained stable during follow-up and was not related to MoCA.

Conclusions

Cognitive function, anxiety and depressive status remain stable in HF patients despite optimized HF therapy. Cognitive status shall be routinely screened to adopt attitudes that improve management as it has an impact on HF-related QoL and prognosis.

认知障碍、焦虑和抑郁在心力衰竭(HF)患者中很常见,其演变尚不完全清楚。目的评估心衰患者长期认知状态、与焦虑、抑郁的关系及其对预后的影响。方法前瞻性、纵向、单中心研究,纳入了因心衰失代偿入院后随访的患者。出院前和随访期间(6 ~ 12个月)分别采用蒙特利尔认知评估(MoCA)、医院焦虑抑郁量表(HADS)和堪萨斯城心肌病问卷对患者的认知功能、焦虑/抑郁状态、hf相关生活质量(QoL)进行评估。HF相关终点为全因再入院、HF再入院和全因再入院或死亡的综合终点。结果纳入43例患者(67±11.3岁,男性69%);随访时间8.2±2.1个月。25.6%的患者MoCA评分异常,随访期间保持稳定(22.6±4.2 vs. 22.2±5.5;p = NS)。出院时MoCA评分<22使HF再入院风险增加6倍[HR=6.42 (1.26-32.61);p=0.025],也预测全因再入院[HR=4.00 (1.15-13.95);p=0.03]和死亡或全因再入院[HR=4.63 (1.37-15.67);p = 0.014)。MoCA评分越高的患者对疾病的处理能力越强(p=0.038)。出院时,抑郁和焦虑的hds评分异常分别为14%和18.6%,随访期间保持稳定,与MoCA无关。结论心衰患者的认知功能、焦虑和抑郁状态在优化心衰治疗后保持稳定。认知状态对hf相关生活质量和预后有影响,应常规筛查,采取改善管理的态度。
{"title":"Heart and brain interactions in heart failure: Cognition, depression, anxiety, and related outcomes","authors":"Joana Rigueira ,&nbsp;João R. Agostinho ,&nbsp;Inês Aguiar-Ricardo ,&nbsp;Inês Gonçalves ,&nbsp;Rafael Santos ,&nbsp;Afonso Nunes-Ferreira ,&nbsp;Tiago Rodrigues ,&nbsp;Nelson Cunha ,&nbsp;N’Zinga André ,&nbsp;Raquel Pires ,&nbsp;Fátima Veiga ,&nbsp;Mónica Mendes Pedro ,&nbsp;Fausto J. Pinto ,&nbsp;Dulce Brito","doi":"10.1016/j.repce.2020.09.008","DOIUrl":"10.1016/j.repce.2020.09.008","url":null,"abstract":"<div><h3>Background</h3><p>Cognitive impairment, anxiety and depression are common in heart failure (HF) patients and its evolution is not fully understood.</p></div><div><h3>Objectives</h3><p>To assess the cognitive status of HF patients over time, its relation to anxiety and depression, and its prognostic impact.</p></div><div><h3>Methods</h3><p>Prospective, longitudinal, single center study including patients enrolled in a structured program for follow-up after hospital admission for HF decompensation. Cognitive function, anxiety/depression state, HF-related quality of life (QoL) were assessed before discharge and during follow-up (between 6<sup>th</sup> and 12<sup>th</sup> month) using Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS) and Kansas City Cardiomyopathy Questionnaire, respectively. HF related outcomes were all cause readmissions, HF readmissions and the composite endpoint of all-cause readmissions or death.</p></div><div><h3>Results</h3><p>43 patients included (67±11.3 years, 69% male); followed-up for 8.2±2.1 months. 25.6% had an abnormal MoCA score that remained stable during follow-up (22.6±4.2 vs. 22.2±5.5; p=NS). MoCA score &lt;22 at discharge conferred a sixfold greater risk of HF readmission [HR=6.42 (1.26-32.61); p=0.025], also predicting all-cause readmissions [HR=4.00 (1.15-13.95); p=0.03] and death or all-cause readmissions [HR=4.63 (1.37-15.67); p=0.014]. Patients with higher MoCA score showed a greater ability to deal with their disease (p=0.038). At discharge, 14% and 18.6% had an abnormal HADS score for depression and anxiety, respectively, which remained stable during follow-up and was not related to MoCA.</p></div><div><h3>Conclusions</h3><p>Cognitive function, anxiety and depressive status remain stable in HF patients despite optimized HF therapy. Cognitive status shall be routinely screened to adopt attitudes that improve management as it has an impact on HF-related QoL and prognosis.</p></div>","PeriodicalId":101121,"journal":{"name":"Revista Portuguesa de Cardiologia (English Edition)","volume":"40 8","pages":"Pages 547-555"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.repce.2020.09.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39311722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Percutaneous patent ductus arteriosus closure: Twelve years of experience 经皮动脉导管未闭闭合:12年经验
Pub Date : 2021-08-01 DOI: 10.1016/j.repce.2020.09.009
João Antunes Sarmento , Ana Correia-Costa , Edite Gonçalves , Maria João Baptista , João Carlos Silva , Jorge Moreira

Introduction

Patent ductus arteriosus, a persistent communication between the descending thoracic aorta and the pulmonary artery, is one of the most common congenital heart defects. Transcatheter occlusion is an effective alternative to surgery and is currently standard of care for most patients. The authors present the results from a single center after twelve years of experience using this technique.

Methods

Retrospective analysis of medical records from all patients referred to a tertiary center for percutaneous ductus closure between January 2006 and September 2018.

Results

A total of 221 patients were referred, with a mean age of 5.5 years-old (16 patients were infants, with the youngest aged four months). A Nit-Occlud® coil was used 139 times (62.9%), an Amplatzer™ duct occluder 79 times (35.7%), and vascular plugs were used three times. Percutaneous closure was achieved in every treated patient, with 1.4% maintaining residual shunting. Although higher overall coil device implantation was noted, duct occluder usage has been greater since 2011. Of all the coils, 55% were either 4x4 or 5x4 mm, and 73% of all Amplatzer duct occluders were either 6x4 or 8x6 mm, which correlates to the majority of patients having a small to moderately sized ductus. No complications were noted during the procedure, with a 1.8% post-procedure complication rate (one device embolization after 48 hours and three cases of loss of arterial pulse).

Conclusions

Percutaneous patent ductus arteriosus closure was safe and effective in this setting, with a low global complication rate and similar outcomes to most equivalent centers.

动脉导管未闭是胸降主动脉和肺动脉之间的一种持续的交通,是最常见的先天性心脏缺陷之一。经导管闭塞是一种有效的替代手术,目前是大多数患者的标准护理。作者介绍了使用该技术12年后单个中心的结果。方法回顾性分析2006年1月至2018年9月在三级中心进行经皮导管闭合的所有患者的病历。结果共纳入221例患者,平均年龄5.5岁(16例为婴儿,最小4个月)。niti - occlud®线圈使用139次(62.9%),Amplatzer™导管闭塞器使用79次(35.7%),血管塞使用3次。所有接受治疗的患者均实现了经皮闭合,1.4%的患者维持了残留的分流。虽然注意到线圈装置植入的总体增加,但自2011年以来,导管闭塞器的使用有所增加。在所有线圈中,55%为4x4或5x4毫米,73%的Amplatzer导管闭塞器为6x4或8x6毫米,这与大多数患者的小到中等大小的导管有关。术中无并发症,术后并发症发生率为1.8%(1例48小时后器械栓塞,3例动脉脉搏消失)。结论经皮动脉导管未闭闭合术安全有效,整体并发症发生率低,结果与大多数同等中心相似。
{"title":"Percutaneous patent ductus arteriosus closure: Twelve years of experience","authors":"João Antunes Sarmento ,&nbsp;Ana Correia-Costa ,&nbsp;Edite Gonçalves ,&nbsp;Maria João Baptista ,&nbsp;João Carlos Silva ,&nbsp;Jorge Moreira","doi":"10.1016/j.repce.2020.09.009","DOIUrl":"10.1016/j.repce.2020.09.009","url":null,"abstract":"<div><h3>Introduction</h3><p>Patent ductus arteriosus, a persistent communication between the descending thoracic aorta and the pulmonary artery, is one of the most common congenital heart defects. Transcatheter occlusion is an effective alternative to surgery and is currently standard of care for most patients. The authors present the results from a single center after twelve years of experience using this technique.</p></div><div><h3>Methods</h3><p>Retrospective analysis of medical records from all patients referred to a tertiary center for percutaneous ductus closure between January 2006 and September 2018.</p></div><div><h3>Results</h3><p>A total of 221 patients were referred, with a mean age of 5.5 years-old (16 patients were infants, with the youngest aged four months). A Nit-Occlud® coil was used 139 times (62.9%), an Amplatzer™ duct occluder 79 times (35.7%), and vascular plugs were used three times. Percutaneous closure was achieved in every treated patient, with 1.4% maintaining residual shunting. Although higher overall coil device implantation was noted, duct occluder usage has been greater since 2011. Of all the coils, 55% were either 4x4 or 5x4 mm, and 73% of all Amplatzer duct occluders were either 6x4 or 8x6 mm, which correlates to the majority of patients having a small to moderately sized ductus. No complications were noted during the procedure, with a 1.8% post-procedure complication rate (one device embolization after 48 hours and three cases of loss of arterial pulse).</p></div><div><h3>Conclusions</h3><p>Percutaneous patent ductus arteriosus closure was safe and effective in this setting, with a low global complication rate and similar outcomes to most equivalent centers.</p></div>","PeriodicalId":101121,"journal":{"name":"Revista Portuguesa de Cardiologia (English Edition)","volume":"40 8","pages":"Pages 561-568"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.repce.2020.09.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39311725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Left main stenosis: Can a consensus be reached? 左主干狭窄:能否达成共识?
Pub Date : 2021-08-01 DOI: 10.1016/j.repce.2021.07.032
Pedro Magro, Miguel Sousa-Uva
{"title":"Left main stenosis: Can a consensus be reached?","authors":"Pedro Magro,&nbsp;Miguel Sousa-Uva","doi":"10.1016/j.repce.2021.07.032","DOIUrl":"10.1016/j.repce.2021.07.032","url":null,"abstract":"","PeriodicalId":101121,"journal":{"name":"Revista Portuguesa de Cardiologia (English Edition)","volume":"40 8","pages":"Pages 619-622"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.repce.2021.07.032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39311729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insulin resistance as a predictor of cardiovascular diseases 胰岛素抵抗是心血管疾病的预测因子
Pub Date : 2021-08-01 DOI: 10.1016/j.repce.2021.07.025
Neuza Domingues
{"title":"Insulin resistance as a predictor of cardiovascular diseases","authors":"Neuza Domingues","doi":"10.1016/j.repce.2021.07.025","DOIUrl":"10.1016/j.repce.2021.07.025","url":null,"abstract":"","PeriodicalId":101121,"journal":{"name":"Revista Portuguesa de Cardiologia (English Edition)","volume":"40 8","pages":"Pages 545-546"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.repce.2021.07.025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39322991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Basal takotsubo syndrome: A multifaceted entity with potential implications 基底takotsubo综合征:具有潜在影响的多方面实体
Pub Date : 2021-08-01 DOI: 10.1016/j.repce.2021.07.033
Kenan Yalta , Cihan Ozturk , Tulin Yalta , Ertan Yetkin
{"title":"Basal takotsubo syndrome: A multifaceted entity with potential implications","authors":"Kenan Yalta ,&nbsp;Cihan Ozturk ,&nbsp;Tulin Yalta ,&nbsp;Ertan Yetkin","doi":"10.1016/j.repce.2021.07.033","DOIUrl":"10.1016/j.repce.2021.07.033","url":null,"abstract":"","PeriodicalId":101121,"journal":{"name":"Revista Portuguesa de Cardiologia (English Edition)","volume":"40 8","pages":"Pages 625-626"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.repce.2021.07.033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39311161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Prognostic impact of iron deficiency in acute coronary syndromes 铁缺乏对急性冠脉综合征患者预后的影响
Pub Date : 2021-08-01 DOI: 10.1016/j.repce.2020.09.005
Carina Silva , Juliana Martins , Isabel Campos , Carina Arantes , Carlos Galvão Braga , Nuno Salomé , António Gaspar , Pedro Azevedo , Miguel Álvares Pereira , Jorge Marques , Catarina Vieira

Background

Iron deficiency (IDef) is a prevalent condition in patients with heart disease and in those with heart failure (HF). Evidence has shown that this deficit is associated with worse prognosis. Data in literature are scarce on the prognostic impact of IDef in acute coronary syndromes (ACS), which is the main objective of this study.

Methods

Observational, retrospective study which included 817 patients admitted for ACS. Two groups were defined according to the presence (n=298) or absence of IDef (n=519) on admission. The clinical event under study was the occurrence of death or severe HF in the long term. Independent predictors of prognosis were determined with logistic regression analysis.

Results

Thirty-six percent of patients had IDef. There was higher mortality (p=0.004), higher incidence of HF (p=0.011) during follow-up and a higher rate of hospital readmissions (p=0.048) in this group. IDef was an independent predictor of death or severe HF in follow-up, along with anemia, left ventricular dysfunction, renal dysfunction and the absence of revascularization. IDef also enabled us to further stratify the prognosis of patients without anemia based on the occurrence of death or severe HF and those with lower Killip classes (≤2) based on the occurrence of death.

Conclusion

IDef was an independent predictor of death or severe HF in patients admitted with ACS and enabled additional stratification for those without anemia on admission and in those with Killip classes ≤2.

背景:缺铁(IDef)是心脏病和心力衰竭(HF)患者的普遍状况。有证据表明,这种缺陷与较差的预后有关。关于急性冠脉综合征(ACS)中IDef对预后影响的文献资料很少,这是本研究的主要目的。方法采用观察性、回顾性研究,纳入817例ACS患者。根据入院时是否存在IDef (n=298)和是否存在IDef (n=519)分为两组。所研究的临床事件是长期发生死亡或严重HF。采用logistic回归分析确定预后的独立预测因素。结果36%的患者有idf。随访期间死亡率较高(p=0.004),心衰发生率较高(p=0.011),再入院率较高(p=0.048)。IDef是随访中死亡或严重HF、贫血、左心室功能障碍、肾功能障碍和缺乏血运重建的独立预测因子。IDef还使我们能够根据死亡或严重HF的发生对无贫血患者的预后进行进一步分层,根据死亡的发生对Killip分级较低(≤2)的患者进行预后分层。结论:idef是ACS患者死亡或严重心衰的独立预测因子,可对入院时无贫血和Killip分级≤2的患者进行进一步分层。
{"title":"Prognostic impact of iron deficiency in acute coronary syndromes","authors":"Carina Silva ,&nbsp;Juliana Martins ,&nbsp;Isabel Campos ,&nbsp;Carina Arantes ,&nbsp;Carlos Galvão Braga ,&nbsp;Nuno Salomé ,&nbsp;António Gaspar ,&nbsp;Pedro Azevedo ,&nbsp;Miguel Álvares Pereira ,&nbsp;Jorge Marques ,&nbsp;Catarina Vieira","doi":"10.1016/j.repce.2020.09.005","DOIUrl":"10.1016/j.repce.2020.09.005","url":null,"abstract":"<div><h3>Background</h3><p>Iron deficiency (IDef) is a prevalent condition in patients with heart disease and in those with heart failure (HF). Evidence has shown that this deficit is associated with worse prognosis. Data in literature are scarce on the prognostic impact of IDef in acute coronary syndromes (ACS), which is the main objective of this study.</p></div><div><h3>Methods</h3><p>Observational, retrospective study which included 817 patients admitted for ACS. Two groups were defined according to the presence (n=298) or absence of IDef (n=519) on admission. The clinical event under study was the occurrence of death or severe HF in the long term. Independent predictors of prognosis were determined with logistic regression analysis.</p></div><div><h3>Results</h3><p>Thirty-six percent of patients had IDef. There was higher mortality (p=0.004), higher incidence of HF (p=0.011) during follow-up and a higher rate of hospital readmissions (p=0.048) in this group. IDef was an independent predictor of death or severe HF in follow-up, along with anemia, left ventricular dysfunction, renal dysfunction and the absence of revascularization. IDef also enabled us to further stratify the prognosis of patients without anemia based on the occurrence of death or severe HF and those with lower Killip classes (≤2) based on the occurrence of death.</p></div><div><h3>Conclusion</h3><p>IDef was an independent predictor of death or severe HF in patients admitted with ACS and enabled additional stratification for those without anemia on admission and in those with Killip classes ≤2.</p></div>","PeriodicalId":101121,"journal":{"name":"Revista Portuguesa de Cardiologia (English Edition)","volume":"40 8","pages":"Pages 525-536"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.repce.2020.09.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39311718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Revista Portuguesa de Cardiologia (English Edition)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1